Management of peptic ulcers: Emerging issues

World Journal of Surgery

Volumn 24, Issue 3, 2000, Pages 250-255

  Freston, James W ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; BISMUTH; CLARITHROMYCIN; FAMOTIDINE; LANSOPRAZOLE; METRONIDAZOLE; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE; RANITIDINE BISMUTH CITRATE; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BREATH ANALYSIS; CONTROLLED STUDY; ERADICATION THERAPY; GASTROESOPHAGEAL REFLUX; GRAM NEGATIVE INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; PATIENT COMPLIANCE; PEPTIC ULCER; SEROLOGY; TREATMENT FAILURE;

ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; DRUG THERAPY, COMBINATION; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER; RECURRENCE; RISK FACTORS; TREATMENT FAILURE;

EID: 0034001790     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002689910040     Document Type: Article

References (47)

1. Lee, J., O'Morain, C.: Who should be treated for Helicobacter pylori infection? A review of consensus conferences and guidelines. Gastroenterology 113(Suppl. 1)S99, 1997
2. European Helicobacter pylori Study Group (EHPSG): Current European concepts in the management of H. pylori infection: the Maastricht consensus report. Gut 41:8, 1997
3. Report of the Digestive Health Initiative International Update Conference on Helicobacter pylori. Gastroenterology 113:(Suppl. 1)S4, 1997
4. Hunt, R.H., Thompson, A.: Canadian Helicobacter pylori consensus conference. Can. J. Gastroenterol. 12:31, 1998
5. Cave, D.R.: How is Helicobacter pylori transmitted? Gastroenterology. 113(Suppl. 1):S9, 1997
6. Cover, T.L.: Commentary: Helicobacter pylori transmission, host factors, and bacterial factors. Gastroenterology 113(Suppl. 1):S29, 1997
7. Malfertheiner, P., Freston, J.W.: Helicobacter pylori-induced gastric and ulceration: epidemiology, pathophysiology and therapeutics. In: Gastrointestinal Pharmacology and Therapeutics, E.D. Jacobson, editor, Philadelphia, Lippincott-Raven, 1997, pp. 21-29
8. Cutler, A.F., Havstad, S., Ma, C., Blaser, M., Perez-Perez, G., Shubert, T.: Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection. Gastroenterology 109:136, 1995
9. 14C urea breath test. Am. J. Gastroenterol. 91:89, 1996
10. 14C-urea breath test by a pH-dependent mechanism. Am. J. Gastroenterol. 92:446, 1997
11. Laine, L., Lewin, D., Naritoku, W., Estrada, R., Cohen, H.: Prospective comparison of commercially available rapid urease tests for the diagnosis of Helicobacter pylori. Gastrointest. Endosc. 44:523, 1996
12. Megraud, F.: How should Helicobacter pylori infection be diagnosed? Gastroenterology 113(Suppl. 1):S93, 1997
13. Howden, C.W.: For what conditions is there evidence-based justification for treatment of Helicobacter pylori infection? Gastroenterology 113(Suppl. 1):S78, 1997
14. Taylor, J.L., Zagari, M., Murphy, K., Freston, J.W.: Pharmacoeconomic comparison of treatments for the eradication of H. pylori. Arch. Intern. Med. 157:87, 1997
15. Unge, P.: What other regimens are under investigation to treat Helicobacter pylori infection? Gastroenterology 113(Suppl. 1):S131, 1997
16. Huang, J.Q., Chiba, N., Wilkinson, J.M., Hunt, R.H.: One week clarithromycin 500 mg bid is better than 250 mg bid for eradicating Helicobacter pylori (H. pylori) infection when combined with proton pump inhibitor and metronidazole or amoxicillin: a meta-analysis [abstract]. Gastroenterology 112:A153, 1997
17. Peterson, W.L., Ciociola, A.A., Sykes, D.L., McSorley, D.J., Webb, D.D.: Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. Aliment. Pharmacol. Ther. 10:251, 1996
18. Huang, J.Q., Chiba, N., Wilkinson, J.M., Hunt, R.H.: Which combination therapy can eradicate > 90% Helicobacter pylori (H. pylori) infection? A meta-analysis of amoxicillin, metronidazole, tetracycline and clarithromycin containing regimens [abstract]. Gastroenterology 112:A19, 1997
19. Freston, J.W.: What remaining questions regarding Helicobacter pylori and associated diseases should be addressed by future research? View from North America. Gastroenterology 113:(Suppl. 1)S163, 1997
20. Czinn, S.J.: What is the role for vaccination in Helicobacter pylori? Gastroenterology 113(Suppl. 1):S149, 1997
21. Forbes, G.M., Glasser, M.E., Cullen, D.J.E., Warren, J.R., Christiansen, K.J., Marshall, B.J., Collins, B.J.: Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up. Lancet 343:258, 1994
22. Vaira, D., Menegatti, M., Miglioli, M.: What is the role of Helicobacter pylori in complicated ulcer disease? Gastroenterology 113(Suppl. 1):S78, 1997
23. Borody, T.J., Shortis, N.P.: Treatment of patients with failed eradication: a personal view. In: Helicobacter pylori: Basic Mechanisms to Clinical Cure 1996, R. Hunt, G.N.J. Tytgat, editors, Dordrecht, Kluwer, 1996, pp. 357-365
24. Freston, J.W.: Helicobacter pylori: The Clinical Agenda. In: Helicobacter pylori: Basic Mechanisms to Clinical Cure 1998, R. Hunt, G.N.J. Tytgat, editors, Dordrecht, Kluwer, 1998, pp. 1-9
25. Breuer, T., Goodman, K.J., Malaty, H.M., Sudhop, T., Graham, D.Y.: How do clinicians practicing in the U.S. manage Helicobacter pylori-related gastrointestinal diseases? A comparison of primary care and specialist physicians. Am. J. Gastroenterol. 93:553, 1998
26. Graham, D.Y., Lew, G.M., Malaty, H.M., Evans, D.J., Klein, P.D., Alpert, L.C., Genta, R.M.: Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 102:493, 1992
27. Vakil, N., Fennerty, B.: Cost-effectiveness of treatment regimens for H. pylori-infection based on a community practice effectiveness study [abstract]. Gastroenterology 112:A28, 1997
28. Cayla, R., Zerbib, F., Talbi, P., Megraud, F., Lamouliatte, H.: Pre and post treatment clarithromycin resistance of Helicobacter pylori strains: a key factor of treatment failure [abstract]. Gut 37(Suppl. 1):A55, 1995
29. Megraud, F.: What is the relevance of resistance of Helicobacter pylori to antimicrobial agents? In: Helicobacter pylori: Basic Mechanisms to Clinical Cure 1996, R. Hunt, G.N.J. Tytgat, editors, Dordrecht, Kluwer, 1996, pp. 348-356
30. Megraud, F., Camou-Juncas, C., Occhialini, A., Birac, C.: Helicobacter pylori resistance levels to clarithromycin remain stable [abstract]. Gastroenterology 100:A192, 1996
31. Lind, T., Megraud, F., Bardhan, K.D., Bayerdorffer, E., Hellblom, M., O'Morain, C., Spiller, R.C., Unge, P., Veldhuyzen van Zanten, S.J.O., Wrangstadh, M., Zeijlon, L., Cederberg, C.: The MACH2 study: antimicrobial resistance in Helicobacter pylori therapy - the impact of omeprazole [abstract]. Gut 41(Suppl. 1):A89, 1997
32. Hallerback, B., Unge, P., Carling, L., Edwin, B., Glise, H., Havu, N., Lyrenas, E., Lundberg, K.: Omeprazole or ranitidine in long-term treatment of reflux esophagitis: the Scandinavian Clinics for United Research group. Gastroenterology 107:1305, 1994
33. Mihara, M., Haruma, K., Kamada, T., Kiyohira, K., Goto, T., Sumii, M., Tanaka, S., Yoshihara, M., Sumii, K., Kajiyama, G.: Low prevalence of Helicobacter pylori infection in patients with reflux esophagitis [abstract]. Gut 39(Suppl. 2):A94, 1996
34. Kuipers, E.J., Uterlinde, A.M., Pena, A.S., Roosendaal, R., Pals, G., Nelis, G.F., Festen, H.P., Meuwissen, S.G.: Long-term sequelae of Helicobacter pylori gastritis. Lancet 345:1525, 1995
35. Labenz, J., Blum, A.L., Bayerdorffer, E., Meining, A., Stolte, M., Borsch, G.: Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 112: 1442, 1997
36. Kuipers, E.J., Lundell, L., Klinkenberg-Knol, E.C., Havu, N., Festen, H.P., Liedman, B., Lamers, C.B., Jansen, J.B., Dalenback, J., Snel, P., Nelis, G.F., Meuwissen, S.G.: Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N. Engl. J. Med. 334:1018, 1996
37. Freston, J.W.: Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective. Am. J. Gastroenterol. 4(Suppl. 1):51S, 1997
38. Lundell, L., Havu, N., Andersson, A., Miettinen, P., Myrvold, H.E., Pedersen, S.A., Thor, K.: Gastritis development and acid suppression therapy revisited: results of a randomized clinical study with long-term follow-up [abstract]. Gastroenterology 112:A28, 1997
39. Chan, F.K.L., Sung, J.J.Y., Chung, S.C.S., To, K.F., Yung, M.Y., Leung, V.K., Lee, Y.T., Chan, C.S., Li, E.K., Woo, J.: Randomized trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 350:975, 1997
40. Hawkey, C.J., Karrasch, J.A., Szczepanski, L., Walker, D.G., Barkun, A., Swannell, A.J., Yeomans, N.D.: Omeprazole compared with misoprostol for ulcers associated with non-steroidal anti-inflammatory drugs: omeprazole vs. misoprostol for NSAID-induced ulcer management. (OMNIUM) Study Group. N. Engl. J. Med. 338:727, 1998
41. Taha, A.S., Hudson, N., Hawkey, C.J., Swannell, A.J., Tyre, P.N., Cottrell, J., Mann, S.G., Simon, T.J., Sturrock, R.D., Russell, R.I.: Famotidine for the prevention of gastric and duodenal ulcers caused by non-steroidal anti-inflammatory drugs. N. Engl. J. Med. 334:1435, 1996
42. Silverstein, F.E., Graham, D.Y., Senior, J.R., Davies, H.W., Struthers, B.J., Bittman, R.M., Geis, G.S.: Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving non-steroidal anti-inflammatory drugs. Ann. Intern. Med. 123:241, 1995
43. Lancaster-Smith, M.J.: Ranitidine in the treatment of non-steroidal anti-inflammatory drug-associated gastric and duodenal ulcers. Gut 32:252, 1991
44. Walan, A., Bader, J.P., Classen, M., Lamers, C.B., Piper, D.W., Rutgersson, K., Eriksson, S.: Effect of omeprazole and ranitidine on ulcer healing and relapse rates in patients with benign gastric ulcer. N. Engl. J. Med. 320:69, 1989
45. Maher, W., Jyotheeswaran, S., Potter, G., Shaw, A., Malkin, M., Joseph, D., Wagner, D., Faiello, P., Chey, W.Y.: An epidemiological study of peptic ulcer disease patients in greater Rochester, New York [abstract]. Gastroenterology 113:A206, 1997
46. Hirschowitz, B.I., Lanas, A.: Intractable peptic ulceration due to aspirin (ASA) abuse in patients who have not had gastric surgery [abstract]. Gastroenterology 113:A149, 1997
47. McColl, K.E.L., El-Nujumi, A.M., Chittajallu, R.S., Dahill, S.W., Dorrian, C.A., El-Omar, E., Penman, I., Fitzsimons, E.J., Drain, J., Graham, H., Ardill, J.E.S., Bessent, R.: A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration. Gut 34:762, 1993